Protocol Calcineurin Inhibitor (CNI) Weaning

Function of Renal Transplant Clinical Trial

Official title:
Prospective, Multicenter, Randomized, Double-blind, Controlled Parallel Group Study Designed to Assess the Risk-benefit Balance of the Gradual Withdrawal of a Calcineurin Inhibitor (Tacrolimus) in Renal Transplant Patients Over 4 Years and Clinically Selected

Status Terminated

Clinical Trial Summary

The main objective of this study is to demonstrate the benefit of the withdrawal of Tacrolimus (Prograf®) on renal function in patients one year after the end of the weaning period. The secondary objectives will focus on assessing the risks and consequences of withdrawal of Tacrolimus (Prograf®).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Function of Renal Transplant

Clinical Trial Details

NCT number	NCT01292525
Study type	Interventional
Source	Nantes University Hospital
Contact
Status	Terminated
Phase	Phase 3
Start date	May 2011
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01443013` - Analysis of Foxp3 and Vimentin Expression in Renal Transplant Recipient	N/A
Completed	`NCT01759862` - Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant	N/A
Active, not recruiting	`NCT01095172` - RituxiMab INDuction in Renal Transplantation	Phase 4
Completed	`NCT00223054` - Polymorphism of the Cytochrome P450-system in Renal Transplants	Phase 4